{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:33:53Z","timestamp":1794335633148,"version":"4.9.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;0.0001); in contrast, CTPC were present in a small fraction of solitary plasmacytoma patients (18%). Higher numbers of CTPC in PB were associated with higher levels of BM infiltration and more adverse prognostic features, together with shorter time to progression from MGUS to MM (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;0.0001) and a shorter survival in MM patients with active disease requiring treatment (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20090.03). In summary, the presence of CTPC in PB as assessed by NGF at diagnosis, emerges as a hallmark of disseminated PCN, higher numbers of PB CTPC being strongly associated with a malignant disease behavior and a poorer outcome of both MGUS and MM.\n                  <\/jats:p>","DOI":"10.1038\/s41408-018-0153-9","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T13:38:34Z","timestamp":1542634714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)"],"prefix":"10.1038","volume":"8","author":[{"given":"L.","family":"Sanoja-Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Flores-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9235-4671","authenticated-orcid":false,"given":"J. J.","family":"Garc\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garc\u00eda-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Corral-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hern\u00e1ndez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u00edez-Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Millacoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B.","family":"Vidriales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Palomera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-1402","authenticated-orcid":false,"given":"R.","family":"R\u00edos-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rez-Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. M.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EuroFlow consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"153_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3324\/haematol.2013.097907","volume":"99","author":"EM Boyle","year":"2014","unstructured":"Boyle, E. M., Davies, F. E., Leleu, X. & Morgan, G. J. Understanding the multiple biological aspects leading to myeloma. Haematologica 99, 605\u2013612 (2014).","journal-title":"Haematologica"},{"key":"153_CR2","unstructured":"McKenna R. W. et al. In World Health Organization Calssification of Tumours of Haematopoietic and Lymphoid Tissue IARC. pp. 200\u2013208 (Lyon, 2008)"},{"key":"153_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"AU Palumbo","year":"2011","unstructured":"Palumbo, A. U. & Anderson, A. U. Multiple myeloma. N. Engl. J. Med. 364, 1046\u20131060 (2011).","journal-title":"N. Engl. J. Med."},{"key":"153_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132391 (2016).","journal-title":"Blood"},{"key":"153_CR5","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"153_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle, R. A. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346, 564\u2013569 (2002).","journal-title":"N. Engl. J. Med."},{"key":"153_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle, R. A. et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 378, 241\u2013249 (2018).","journal-title":"N. Engl. J. Med."},{"key":"153_CR8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","volume":"93","author":"R Garc\u00eda-Sanz","year":"1999","unstructured":"Garc\u00eda-Sanz, R. et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93, 1032\u20131037 (1999).","journal-title":"Blood"},{"key":"153_CR9","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig, C., Knop, S. & Bornh\u00e4user, M. Multiple myeloma. Lancet 385, 2197\u20132208 (2015).","journal-title":"Lancet"},{"key":"153_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1182\/blood-2014-06-579706","volume":"124","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos, M. A. & Terpos, E. Solitary bone plasmacytomas need to flow. Blood 124, 1209\u20131210 (2014).","journal-title":"Blood"},{"key":"153_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1182\/asheducation-2005.1.373","volume":"2005","author":"DM Weber","year":"2005","unstructured":"Weber, D. M. Solitary bone and extramedullary plasmacytoma. Hematol. Am.Soc. Hematol. Educ. Program. 2005, 373\u2013376 (2005).","journal-title":"Hematol. Am.Soc. Hematol. Educ. Program."},{"key":"153_CR12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1182\/blood-2014-04-567909","volume":"124","author":"B Paiva","year":"2014","unstructured":"Paiva, B. et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma. Blood 124, 1300\u20131303 (2014).","journal-title":"Blood"},{"key":"153_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1100\/2012\/895765","volume":"2012","author":"S Kilciksiz","year":"2012","unstructured":"Kilciksiz, S., Karakoyun-Celik, O., Agaoglu, F. Y. & Haydaroglu, A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci. World J. 2012, 1\u20136 (2012).","journal-title":"Sci. World J."},{"key":"153_CR14","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1182\/blood.V88.5.1780.1780","volume":"88","author":"MA Witzig","year":"1996","unstructured":"Witzig, M. A. et al.Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 88, 1780\u20131787 (1996).","journal-title":"Blood"},{"key":"153_CR15","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.V80.7.1818.1818","volume":"80","author":"D Billadeau","year":"1992","unstructured":"Billadeau, D. et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 80, 1818\u20131824 (1992).","journal-title":"Blood"},{"key":"153_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335\u2013348 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"153_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/sj.leu.2403647","volume":"19","author":"M P\u00e9rez-Andr\u00e9s","year":"2005","unstructured":"P\u00e9rez-Andr\u00e9s, M. et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 19, 449\u2013455 (2005).","journal-title":"Leukemia"},{"key":"153_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11914-017-0399-3","volume":"15","author":"M Moschetta","year":"2017","unstructured":"Moschetta, M. et al. Bone marrow stroma and vascular contributions to myeloma bone homing. Curr. Osteoporos. Rep. 15, 499\u2013506 (2017).","journal-title":"Curr. Osteoporos. Rep."},{"key":"153_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood.V88.1.289.289","volume":"88","author":"D Billadeau","year":"1996","unstructured":"Billadeau, D. et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 88, 289\u2013296 (1996).","journal-title":"Blood"},{"key":"153_CR20","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","volume":"23","author":"S Kumar","year":"2005","unstructured":"Kumar, S. et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J. Clin. Oncol. 23, 5668\u20135674 (2005).","journal-title":"J. Clin. Oncol."},{"key":"153_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/bjh.13067","volume":"167","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves, W. I. et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br. J. Haematol. 167, 500\u2013505 (2014).","journal-title":"Br. J. Haematol."},{"key":"153_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00277-014-2211-0","volume":"94","author":"G An","year":"2015","unstructured":"An, G. et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann. Hematol. 94, 257\u2013264 (2015).","journal-title":"Ann. Hematol."},{"key":"153_CR23","doi-asserted-by":"publisher","first-page":"E353","DOI":"10.1002\/ajh.24431","volume":"91","author":"A Periago","year":"2016","unstructured":"Periago, A. et al. Circulating aberrant plasma cells allow risk stratification of patients with myeloma. Am. J. Hematol. 91, E353\u2013E355 (2016).","journal-title":"Am. J. Hematol."},{"key":"153_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","volume":"97","author":"AC Rawstron","year":"1997","unstructured":"Rawstron, A. C. et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br. J. Haematol. 97, 46\u201355 (1997).","journal-title":"Br. J. Haematol."},{"key":"153_CR25","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","volume":"122","author":"B Paiva","year":"2013","unstructured":"Paiva, B. et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood 122, 3591\u20133598 (2013).","journal-title":"Blood"},{"key":"153_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cyto.b.21606","volume":"94","author":"MH Bae","year":"2016","unstructured":"Bae, M. H. et al. Increased circulating plasma cells detected by flowcytometry predicts poor prognosis in patients with plasma cell myeloma. Cytom. B. Clin. Cytom 94, 493\u2013499 (2016).","journal-title":"Cytom. B. Clin. Cytom"},{"key":"153_CR27","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"CF De Larrea","year":"2013","unstructured":"De Larrea, C. F. et al. Plasma cell leukemia. Leukemia 27, 780\u2013791 (2013).","journal-title":"Leukemia"},{"key":"153_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/(SICI)1097-0320(19960615)26:2<113::AID-CYTO3>3.0.CO;2-H","volume":"26","author":"TE Witzig","year":"1996","unstructured":"Witzig, T. E., Kimlinger, T. K., Ahmann, G. J., Katzmann, J. A. & Greipp, P. R. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 26, 113\u2013120 (1996).","journal-title":"Cytometry"},{"key":"153_CR29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/leu.2012.237","volume":"27","author":"G Bianchi","year":"2013","unstructured":"Bianchi, G. et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 27, 680\u2013685 (2013).","journal-title":"Leukemia"},{"key":"153_CR30","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","volume":"106","author":"GS Nowakowski","year":"2005","unstructured":"Nowakowski, G. S. et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 106, 2276\u20132279 (2005).","journal-title":"Blood"},{"key":"153_CR31","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3324\/haematol.2017.166629","volume":"102","author":"R Chakraborty","year":"2017","unstructured":"Chakraborty, R. et al. Serial measurements of circulating plasma cells before and after induction therapy has an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica 102, 1439\u20131445 (2017).","journal-title":"Haematologica"},{"key":"153_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bcj.2016.117","volume":"6","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty, R. et al. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J. 6, 1\u20136 (2016).","journal-title":"Blood Cancer J."},{"key":"153_CR33","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1182\/blood-2005-08-3398","volume":"107","author":"D Dingli","year":"2006","unstructured":"Dingli, D. et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood 107, 3384\u20133388 (2006).","journal-title":"Blood"},{"key":"153_CR34","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero, J. et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094\u20132103 (2017).","journal-title":"Leukemia"},{"key":"153_CR35","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"153_CR36","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"153_CR37","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","volume":"96","author":"MA Dimopoulos","year":"2000","unstructured":"Dimopoulos, M. A., Moulopoulos, L. A., Maniatis, A. & Alexanian, R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96, 2037\u20132044 (2000).","journal-title":"Blood"},{"key":"153_CR38","doi-asserted-by":"crossref","first-page":"1855 LP","DOI":"10.1182\/blood.V126.23.1855.1855","volume":"126","author":"J Fan","year":"2015","unstructured":"Fan, J. et al. Macrofocal multiple myeloma is a particular subgroup of multiple myeloma. Blood 126, 1855 LP\u20131851855 (2015).","journal-title":"Blood"},{"key":"153_CR39","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1080\/10428190600647723","volume":"47","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos, M. A. et al. Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis. Leuk. Lymphoma 47, 1553\u20131556 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"153_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.blre.2015.06.001","volume":"29","author":"MV Mateos","year":"2015","unstructured":"Mateos, M. -V. et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood. Rev. 29, 387\u2013403 (2015).","journal-title":"Blood. Rev."},{"key":"153_CR41","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.clml.2017.06.022","volume":"17","author":"MV Mateos","year":"2017","unstructured":"Mateos, M. V. & Gonz\u00e1lez-Calle, V. Smoldering Multiple Myeloma: Who and When to Treat. Clin. Lymphoma Myeloma Leuk. 17, 716\u2013722 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"153_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.blre.2007.01.002","volume":"21","author":"SV Rajkumar","year":"2007","unstructured":"Rajkumar, S. V., Lacy, M. Q. & Kyle, R. A. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood. Rev. 21, 255\u2013265 (2007).","journal-title":"Blood. Rev."},{"key":"153_CR43","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586\u20132592 (2007).","journal-title":"Blood"},{"key":"153_CR44","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"153_CR45","first-page":"53","volume":"15","author":"P Men\u00e9ndez","year":"2001","unstructured":"Men\u00e9ndez, P., del Ca\u00f1izo, M. C. & Orfao, A. Immunophenotypic characteristics of PB-mobilised CD34\u2009+\u2009hematopoietic progenitor cells. J. Biol. Regul. Homeost. Agents 15, 53\u201361 (2001).","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"153_CR46","first-page":"1","volume":"0","author":"M Arroz","year":"2015","unstructured":"Arroz, M. et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytom. Part B - Clin. Cytom. 0, 1\u20139 (2015).","journal-title":"Cytom. Part B - Clin. Cytom."},{"key":"153_CR47","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/leu.2014.98","volume":"28","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves, W. I. et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high- risk myeloma. Leukemia 28, 2060\u20132065 (2014).","journal-title":"Leukemia"},{"key":"153_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/leu.2016.205","volume":"31","author":"WI Gonsalves","year":"2017","unstructured":"Gonsalves, W. I. et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia 31, 130\u2013135 (2017).","journal-title":"Leukemia"},{"key":"153_CR49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","volume":"78","author":"B Paiva","year":"2010","unstructured":"Paiva, B. et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytom. Part B Clin. Cytom. 78, 239\u2013252 (2010).","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"153_CR50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/1097-0142(19930701)72:1<108::AID-CNCR2820720121>3.0.CO;2-T","volume":"72","author":"TE Witzig","year":"1993","unstructured":"Witzig, T. E., Dhodapkar, M. V., Kyle, R. A. & Greipp, P. R. Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 72, 108\u2013113 (1993).","journal-title":"Cancer"},{"key":"153_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","volume":"14","author":"R Vij","year":"2014","unstructured":"Vij, R. et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin. Lymphoma, Myeloma Leuk. 14, 131\u2013139 (2014).","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"153_CR52","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva, B., Dongen, J. J. M. Van & Orfao, A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125, 3059\u20133069 (2015).","journal-title":"Blood"},{"key":"153_CR53","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bjh.13484","volume":"170","author":"D Vagnoni","year":"2015","unstructured":"Vagnoni, D. et al. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics. Br. J. Haematol. 170, 523\u2013531 (2015).","journal-title":"Br. J. Haematol."},{"key":"153_CR54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2010.320","volume":"25","author":"B Paiva","year":"2011","unstructured":"Paiva, B. et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia 25, 697\u2013706 (2011).","journal-title":"Leukemia"},{"key":"153_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","volume":"120","author":"IM Ghobrial","year":"2012","unstructured":"Ghobrial, I. M. & Dc, W. Myeloma as a model for the process of metastasis: implications for the therapy. Blood 120, 20\u201330 (2012).","journal-title":"Blood"},{"key":"153_CR56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ajh.20125","volume":"77","author":"S Kumar","year":"2004","unstructured":"Kumar, S., Rajkumar, S. V., Greipp, P. R. & Witzig, T. E. Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments. Am. J. Hematol. 77, 7\u201311 (2004).","journal-title":"Am. J. Hematol."},{"key":"153_CR57","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","volume":"19","author":"Y Mishima","year":"2017","unstructured":"Mishima, Y. et al. The mutational landscape of circulating tumor cells in multiple myeloma. Cell Rep. 19, 218\u2013224 (2017).","journal-title":"Cell Rep."},{"key":"153_CR58","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.2015.138826","volume":"101","author":"HE Johnsen","year":"2016","unstructured":"Johnsen, H. E. et al. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica 101, 1451\u20131459 (2016).","journal-title":"Haematologica"},{"key":"153_CR59","first-page":"135","volume":"1","author":"CruzR Dela","year":"2011","unstructured":"Dela, CruzR., Tricot, G., Zangari, M. & Zhan, F. Progress in myeloma stem cells. Am. J. Blood Res. 1, 135\u2013145 (2011).","journal-title":"Am. J. Blood Res."},{"key":"153_CR60","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/cyto.b.20547","volume":"78B","author":"M Perez-Andres","year":"2010","unstructured":"Perez-Andres, M. et al. Human peripheral blood B-cell compartments: A crossroad in B-cell traffic. Cytom. Part B Clin. Cytom. 78B, S47\u2013S60 (2010).","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"153_CR61","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3324\/haematol.2009.018689","volume":"95","author":"A Caraux","year":"2010","unstructured":"Caraux, A. et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138 plasma cells. Haematologica 95, 1016\u20131020 (2010).","journal-title":"Haematologica"},{"key":"153_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero, J. et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytom. Part B Clin. Cytom. 90, 61\u201372 (2016).","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"153_CR63","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood.V94.2.701","volume":"94","author":"G Jego","year":"1999","unstructured":"Jego, G. et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 94, 701\u2013712 (1999).","journal-title":"Blood"},{"key":"153_CR64","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1182\/blood.V99.6.2154","volume":"99","author":"F Medina","year":"2002","unstructured":"Medina, F., Segundo, C., Campos-Caro, A., Gonz\u00e1lez-Garc\u00eda, I. & Brieva, J. A. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 99, 2154\u20132161 (2002).","journal-title":"Blood"},{"key":"153_CR65","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","volume":"26","author":"G Mateo","year":"2008","unstructured":"Mateo, G. et al. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J. Clin. Oncol. 26, 2737\u20132744 (2008).","journal-title":"J. Clin. Oncol."},{"key":"153_CR66","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3324\/haematol.2010.031872","volume":"96","author":"M Schmidt-Hieber","year":"2011","unstructured":"Schmidt-Hieber, M. et al. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica 96, 328\u2013332 (2011).","journal-title":"Haematologica"},{"key":"153_CR67","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/hon.2354","volume":"35","author":"Aacute M\u00e1rk","year":"2017","unstructured":"M\u00e1rk, \u00c1. et al. The effect of microenvironmental factors on the development of myeloma cells. Hematol. Oncol 35, 741\u2013745 (2017).","journal-title":"Hematol. Oncol"},{"key":"153_CR68","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/jcp.47.5.418","volume":"47","author":"H Turley","year":"1994","unstructured":"Turley, H. et al. VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections. J. Clin. Pathol. 47, 418\u2013422 (1994).","journal-title":"J. Clin. Pathol."},{"key":"153_CR69","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/jcp.50.6.485","volume":"50","author":"H Banham a","year":"1997","unstructured":"Banham a, H., Turley, H., Pulford, K., Gatter, K. & Mason, D. Y. The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein. J. Clin. Pathol. 50, 485\u2013489 (1997).","journal-title":"J. Clin. Pathol."},{"key":"153_CR70","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.leukres.2013.06.020","volume":"37","author":"G An","year":"2013","unstructured":"An, G. et al. t (11; 14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk. Res. 37, 1251\u20131257 (2013).","journal-title":"Leuk. Res."},{"key":"153_CR71","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","volume":"28","author":"J Blad\u00e9","year":"2010","unstructured":"Blad\u00e9, J., Dimopoulos, M., Rosi\u00f1ol, L., Rajkumar, S. V. & Kyle, R. A. Smoldering (asymptomatic) multiple myeloma: Current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J. Clin. Oncol. 28, 690\u2013697 (2010).","journal-title":"J. Clin. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0153-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0153-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0153-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T11:11:37Z","timestamp":1720782697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0153-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0153-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"10 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"117"}}